The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19

The treatment with Jusvinza reduces hyperinflammation and hypercoagulation in critical ill patients with COVID-19

Introduction: Infection with SARS-CoV-2 induces a prothrombotic state in patients, by the combination of hyperinflammatory response and hypoxia. In Cuba, the drug called Jusvinza, based on an immunomodulatory peptide, is used for the treatment of patients with COVID-19, who present signs and symptom...

Full description

Saved in:
Bibliographic Details
Main Authors: Rafael Venegas Rodríguez, Anabel Serrano Díaz, Rubén Peña Ruiz, Raúl Santana Sánchez, Aliusha Rittoles Navarro, Inti Grecesqui Cruz, Liam Manuel Pérez Aguilera, Anadys Segura Fernández, Mabel Hernández-Cedeño, Leticia Rosario Cruz, Deyli Chacón Montano, Gillian Martínez-Donato, Gerardo Guillén-Nieto, María del Carmen Domínguez Horta
Format: Article
Language:Spanish
Published: Editorial Ciencias Médicas - ECIMED 2021-11-01
Series:Revista Cubana de Medicina Militar
Subjects:
covid-19
hiperinflamación
hipercoagulación hsp60
cigb-258
jusvinza.
Online Access:http://www.revmedmilitar.sld.cu/index.php/mil/article/view/1675
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.revmedmilitar.sld.cu/index.php/mil/article/view/1675

Similar Items